Search Result

Results for "

PF-044

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (4) Autophagy (2) CGRP Receptor (1) FAAH (2) Isotope-Labeled Compounds (2) mTOR (1) Opioid Receptor (1) Phosphodiesterase (PDE) (3) Prostaglandin Receptor (2) Reference Standards (3) Smo (5)
By Research Areas:	Cancer (9) Endocrinology (2) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (11)

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-18966

PF-04418948 10+ Cited Publications	Prostaglandin Receptor	Endocrinology Cancer
PF-04418948, a chemical probe, is an orally active, potent and selective prostaglandin EP₂ receptor antagonist with an IC₅₀ of 16 nM .

HY-50682

Azeliragon Maximum Cited Publications 15 Publications Verification TTP488; PF-04494700	Amyloid-β	Neurological Disease Cancer
Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .

HY-16391

Glasdegib 5 Publications Verification PF-04449913	Smo	Cancer
Glasdegib (PF-04449913) is a potent and orally bioavailable smoothened inhibitor. Glasdegib (PF-04449913) binds to human SMO (amino acids 181-787) with an IC₅₀ of 4 nM .

HY-14376

Redafamdastat 5+ Cited Publications PF-04457845	FAAH Autophagy	Neurological Disease
Redafamdastat (PF-04457845), a chemical probe, is a highly efficacious and selective FAAH inhibitor with IC₅₀ values is 7.2±0.63 nM and 7.4±0.62 nM for hFAAH and rFAAH, respectively.

HY-P99019

Fremanezumab 2 Publications Verification TEV-48125; LBR-101; PF-04427429; RN-307	CGRP Receptor	Neurological Disease Inflammation/Immunology
Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC₅₀ values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC₅₀ value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine .

HY-15441

Edelinontrine 4 Publications Verification PF-04447943	Phosphodiesterase (PDE)	Neurological Disease
Edelinontrine (PF-04447943) is a potent inhibitor of human recombinant PDE9A (IC₅₀=12 nM) with >78-fold selectivity, respectively, over other PDE family members (IC₅₀>1000 nM).

HY-12788

PF-04449613	Phosphodiesterase (PDE)	Neurological Disease
PF-04449613 is a selective PDE9A inhibitor with an IC50 of 22 nM[1]. PF-04449613 improved motor learning ability in a mouse model[2].

HY-15691

PF-04455242	Opioid Receptor mTOR	Neurological Disease Metabolic Disease
PF-04455242 is an orally bioavailable, blood-brain barrier-permeable κ-opioid receptor (KOR) inhibitor. PF-04455242 blocks in vivo effects induced by KOR and MOR agonists, and elicits KOR-independent outward currents in ventral tegmental area neurons. PF-04455242 promotes energy expenditure and activates the hypothalamic mTOR pathway. PF-04455242 attenuates stress-induced behavioral effects and produces antidepressant-like effects. PF-04455242 can be used in studies related to pain, depression, addictive disorders, and obesity induced by estrogen withdrawal .

HY-14376R

Redafamdastat (Standard) PF-04457845 (Standard)	FAAH Autophagy Reference Standards	Neurological Disease
Redafamdastat (Standard) is the analytical standard of Redafamdastat. This product is intended for research and analytical applications. Redafamdastat (PF-04457845) is a highly efficacious and selective FAAH inhibitor with IC50 values is 7.2±0.63 nM and 7.4±0.62 nM for hFAAH and rFAAH, respectively.

HY-50682S

Azeliragon-d9 TTP488-d₉; PF-04494700-d₉	Isotope-Labeled Compounds Amyloid-β	Neurological Disease Endocrinology
Azeliragon-d₉ (TTP488-d₉) is the deuterium labeled Azeliragon (HY-50682). Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .

HY-122622

PF-04471141 hydrochloride	Phosphodiesterase (PDE)	Others
PF-04471141 (hydrochloride) is a compound that regulates intracellular cAMP and cGMP concentrations. It is a PDE1 inhibitor and has different effects on different PDE enzymes in regulating intracellular signaling molecule concentrations and cell proliferation in vascular smooth muscle cells.

HY-16391S1

Glasdegib-d4 PF-04449913-d₄	Isotope-Labeled Compounds Smo	Cancer
Glasdegib-d₄ (PF-04449913-d₄) is deuterium labeled Glasdegib. Glasdegib (PF-04449913) is a potent and orally bioavailable smoothened inhibitor. Glasdegib (PF-04449913) binds to human SMO (amino acids 181-787) with an IC₅₀ of 4 nM .

HY-16391B

Glasdegib hydrochloride PF-04449913 hydrochloride	Smo	Cancer
Glasdegib hydrochloride is a potent and orally bioavailable smoothened inhibitor. Glasdegib hydrochloride (PF-04449913) binds to human SMO (amino acids 181-787) with an IC₅₀ of 4 nM .

HY-16391A

Glasdegib maleate PF-04449913 maleate	Smo	Cancer
Glasdegib maleate (PF-04449913 maleate) is a potent and orally bioavailable smoothened inhibitor. Glasdegib maleate binds to human SMO (amino acids 181-787) with IC₅₀value of 4 nM .

HY-16391R

Glasdegib (Standard) PF-04449913 (Standard)	Smo Reference Standards	Cancer
Glasdegib (Standard) is the analytical standard of Glasdegib. This product is intended for research and analytical applications. Glasdegib (PF-04449913) is a potent and orally bioavailable smoothened inhibitor. Glasdegib (PF-04449913) binds to human SMO (amino acids 181-787) with an IC50 of 4 nM .

HY-50682R

Azeliragon (Standard) TTP488 (Standard); PF-04494700 (Standard)	Amyloid-β Reference Standards	Neurological Disease Cancer
Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .

HY-50682A

Azeliragon dihydrochloride TTP488 dihydrochloride; PF-04494700 dihydrochloride	Amyloid-β	Neurological Disease Cancer
Azeliragon dihydrochloride (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon dihydrochloride also can cross the blood-brain barrier (BBB) .

HY-185643

PF-04475270	Prostaglandin Receptor	Neurological Disease
PF-04475270 is a prodrug of CP-734432 (HY-119236), as well as an agonist of the EP4 prostaglandin receptor, with IC₅₀ values of 2 nM and 8 nM against human and canine sources, respectively. PF-04475270 is rapidly hydrolyzed into its active metabolite CP-734432 by ocular esterases or corneal homogenate, stimulates cAMP production, and activates cAMP response element-mediated β-lactamase activity in cells expressing EP4. PF-04475270 can be used in research related to glaucoma .

Cat. No.	상품명	Target	Research Area	Image

HY-P99019

Fremanezumab 2 Publications Verification TEV-48125; LBR-101; PF-04427429; RN-307	CGRP Receptor	Neurological Disease Inflammation/Immunology
Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC₅₀ values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC₅₀ value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine .

Cat. No.	상품명	Chemical Structure

HY-50682S

Azeliragon-d9
Azeliragon-d₉ (TTP488-d₉) is the deuterium labeled Azeliragon (HY-50682). Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .

HY-16391S1

Glasdegib-d4
Glasdegib-d₄ (PF-04449913-d₄) is deuterium labeled Glasdegib. Glasdegib (PF-04449913) is a potent and orally bioavailable smoothened inhibitor. Glasdegib (PF-04449913) binds to human SMO (amino acids 181-787) with an IC₅₀ of 4 nM .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
이메일 *

	Sorry, but the email address you supplied was invalid.